Online citations, reference lists, and bibliographies.
← Back to Search

PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA

Tommaso Claudio Mineo and Vincenzo Ambrogi
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma is an extremely aggressive neoplasm with a poor prognosis. Conventional medical, physical and surgical treatments and their combinations are basically ineffective. Just a few subjects experience some benefit. In the present review we evaluated the impact on prognosis of some conventional factor (i.e. age, gender, histology, staging) as well as relatively new clinical factors such as quality of life, positron emission tomography assessment, occult residual disease. Furthermore, many biological and genetic markers have been recently recognized at the bases of the onset and growth of mesothelioma. These novel factors may play an important role in defining the prognosis of the disease and eventually they might have an hypothetical usefulness in addressing therapy.
This paper references
10.1038/sj.bjc.6690158
Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast
R. Leek (1999)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1016/j.jtcvs.2009.02.046
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
10.1593/NEO.04271
Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.
Z. Liu (2004)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
10.1007/s00280-006-0243-4
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
C. Porta (2006)
10.1093/CARCIN/23.7.1127
Alterations of the p16(INK4) locus in human malignant mesothelial tumors.
T. Hirao (2002)
10.1007/s004320050171
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma
E. Tolnay (1998)
10.1054/bjoc.2001.1997
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1002/cncr.24886
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
10.1007/978-3-642-10862-4_4
Biopsy techniques for the diagnosis of mesothelioma.
J. Walters (2011)
10.1016/J.LUNGCAN.2005.03.009
Prognostic factors in mesothelioma.
J. Steele (2002)
10.1016/J.ATHORACSUR.2005.06.014
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
D. Rice (2005)
10.1096/fj.01-0299fje
COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib
S. Grösch (2001)
10.1016/J.JTCVS.2006.06.044
Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2007)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1016/j.jtcvs.2008.02.069
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1097/MCP.0b013e32812144bb
Biomarkers for mesothelioma
A. Scherpereel (2007)
10.1016/J.JTCVS.2005.11.044
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
F. Bénard (1999)
10.3892/IJO.18.2.425
Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas.
T. Papp (2001)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.1016/S0959-8049(03)00233-8
Analysis of survival of mesothelioma cases in the Italian register (ReNaM).
A. Marinaccio (2003)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1093/JNCI/95.8.598
Using gene expression ratios to predict outcome among patients with mesothelioma.
G. Gordon (2003)
Matrix metalloproteinases and cancer.
G. Cox (2001)
10.1016/j.athoracsur.2009.04.038
Placenta growth factor expression has prognostic value in malignant pleural mesothelioma.
E. Pompeo (2009)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
10.1073/pnas.0604008103
TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis
H. Yang (2006)
10.1593/NEO.06148
p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.
S. Hopkins-Donaldson (2006)
10.1046/J.1365-2559.2000.00888.X
Immunoreactivity for cadherins, HGF/SF, met, and erbB‐2 in pleural malignant mesotheliomas
I. Thirkettle (2000)
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
J. Edwards (2002)
10.1172/JCI23412
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.
G. Glinsky (2005)
10.1016/0007-0971(83)90068-2
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
10.1016/S0891-5849(03)00060-1
Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases.
A. Shukla (2003)
10.1158/1078-0432.CCR-07-1388
Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts
P. Bertino (2008)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
A. Petit (1997)
10.1016/J.LUNGCAN.2005.05.025
Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma.
N. Kokturk (2005)
10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G
Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c‐met receptor
J. Klominek (1998)
10.1016/J.JTCVS.2009.11.072
Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
A. Mujoomdar (2010)
10.1074/jbc.M709698200
Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids*
D. Barbone (2008)
10.1016/j.ejcts.2007.09.045
PTEN expression is a strong predictor of survival in mesothelioma patients.
I. Opitz (2008)
10.1002/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2
The gene for the cyclin‐dependent‐kinase‐4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma
J. Prins (1998)
10.1165/AJRCMB.24.4.4290
Different accumulation of activated extracellular signal-regulated kinases (ERK 1/2) and role in cell-cycle alterations by epidermal growth factor, hydrogen peroxide, or asbestos in pulmonary epithelial cells.
S. Buder-Hoffmann (2001)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1136/thx.2003.008912
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma
A. Baldi (2004)
10.1200/JCO.1993.11.6.1172
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)
10.1053/j.semtcvs.2009.07.001
Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.
J. Friedberg (2009)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
10.1158/1078-0432.CCR-10-2873
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin
P. A. Zucali (2011)
10.1016/S0092-8674(00)81401-4
ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways
Y. Zhang (1998)
10.1159/000321370
A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma
A. C. Tanrıkulu (2010)
10.1016/j.lungcan.2009.04.008
COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
S. O'Kane (2010)
10.1200/JCO.2009.25.9275
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
L. Righi (2010)
10.1016/j.ctrv.2011.01.001
Advances in the biology of malignant pleural mesothelioma.
P. Zucali (2011)
10.1016/S0960-9822(01)00572-3
DNA replication checkpoint
M. N. Boddy (2001)
10.1159/000087376
Serum PDGF-AB in Pleural Mesothelioma
R. Filiberti (2005)
10.1097/JTO.0b013e3181951ce8
In Arrayed Ranks: Array Technology in the Study of Mesothelioma
S. Gray (2009)
10.1158/0008-5472.CAN-09-3993
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.
H. Pass (2010)
10.1126/science.274.5293.1672
Cancer Cell Cycles
C. Sherr (1996)
Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer.
K. Uefuji (2000)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
10.1016/J.LUNGCAN.2005.10.016
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
A. Destro (2006)
10.1038/sj.onc.1206593
Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours
J. Fleury-Feith (2003)
10.1126/SCIENCE.1846706
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
D. Bottaro (1991)
10.1159/000127577
Mesothelioma and Asbestos-Related Pleural Diseases
L. Greillier (2008)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1002/ijc.21271
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma
J. Cortese (2006)
10.1073/pnas.0604544103
Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters
B. Kroczynska (2006)
10.1046/j.1365-2559.2000.00793.x
MIB‐1 proliferation index correlates with survival in pleural malignant mesothelioma
Comin (2000)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1136/oem.56.8.505
Mesothelioma: cases associated with non-occupational and low dose exposures.
G. Hillerdal (1999)
10.1016/0169-5002(95)90162-0
Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer.
Y. Sekido (1995)
10.1093/jjco/hyq159
Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.
S. Nojiri (2011)
10.1200/JCO.2005.04.6813
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1152/ajplung.1998.275.1.L165
Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax.
S. Narasimhan (1998)
10.1016/J.LUNGCAN.2004.04.025
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.
K. O'Byrne (2004)
10.1165/AJRCMB.25.1.4472
Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines.
W. Liu (2001)
10.1002/path.1125
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival
L. Strizzi (2002)
10.1289/EHP.021101003
Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species.
A. Xu (2002)
10.1002/1097-0142(20010901)92:5<1245::AID-CNCR1444>3.0.CO;2-G
p27kip1 immunoreactivity correlates with long‐term survival in pleural malignant mesothelioma
M. Bongiovanni (2001)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1038/bjc.1990.207
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
H. Dazzi (1990)
10.1177/039463200902200216
Placenta Growth Factor is a Survival Factor for Human Malignant Mesothelioma Cells
L. Albonici (2009)
10.1378/chest.109.3_supplement.21s
Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8.
V. Antony (1996)
10.1016/j.athoracsur.2008.01.088
The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
T. Mineo (2008)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1158/0008-5472.CAN-05-2028
Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961.
Rochelle Cutrone (2005)
10.1158/1078-0432.CCR-06-0472
Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma
M. Onda (2006)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
10.1016/0167-4781(95)00196-4
Regulation of differential expression of platelet-derived growth factor α- and β-receptor mRNA in normal and malignant human mesothelial cell lines
A. W. Langerak (1996)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1378/CHEST.124.5.1916
Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma.
J. Edwards (2003)
10.1097/JTO.0b013e3181ec18db
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
10.1016/j.ejcts.2010.02.012
May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
T. Mineo (2010)
10.1158/1078-0432.CCR-04-1884
P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma
A. Borczuk (2005)
10.1158/0008-5472.CAN-04-2461
Evidence against a role for SV40 in human mesothelioma.
J. Manfredi (2005)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1016/J.JTCVS.2006.03.068
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
10.1067/MTC.2000.106529
Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
D. Schneider (2000)
10.1097/JTO.0b013e31819f2e0e
Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure
H. Roberts (2009)
10.1016/j.athoracsur.2010.04.110
Characteristics of malignant pleural mesothelioma in women.
A. Wolf (2010)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
Asbestos bodies in lung tissue are associated with pathologic features and patient outcome for epithelial but not non-epithelial mesothelioma treated by extrapleural pneumonectomy
W. Richards (2009)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.1016/j.lungcan.2008.02.013
Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma.
N. Kobayashi (2008)
10.1002/jso.21261
Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma
V. Ambrogi (2009)
10.1111/J.1749-6632.1991.TB24461.X
Asbestos Disease at Low Exposures after Long Residence Times
G. K. Sluis‐Cremer (1991)
10.1038/sj.bjc.6600920
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura
J. Edwards (2003)
10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M
Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two‐hit mechanism of NF2 inactivation
J. Cheng (1999)
The clinical evaluation of chemotherapeutic agents in cancer
Da Karnofsky (1949)
10.1002/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6
Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene
B. Deguen (1998)
10.1158/0008-5472.CAN-05-3907
Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.
Fernando López-Ríos (2006)
10.1200/JCO.1998.16.9.3158
Tumor-suppressor p53: implications for tumor development and prognosis.
D. Kirsch (1998)
10.1510/ICVTS.2005.123430
The MARS trial: mesothelioma and radical surgery.
T. Treasure (2006)
10.1053/RMED.2001.1108
p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure.
R. Işık (2001)
10.1158/1078-0432.CCR-08-0360
Osteopontin Levels in an Asbestos-Exposed Population
E. Park (2009)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.3109/07357909609018904
Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers.
B. Mossman (1996)
10.1136/thorax.57.4.353
Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival
A. Baldi (2002)
p14ARF Modulates the Cytolytic Effect of ONYX-015 in Mesothelioma Cells with Wild-type p53
C. Yang (2001)
10.3892/OR.8.6.1375
Mutational analysis of the PTEN/MMAC1 tumour suppressor gene in primary human malignant mesotheliomas.
T. Papp (2001)
10.1016/S0761-8417(06)75427-X
La tomographie par émission de positons (TEP) au 18-fluoro-déoxy-glucose (18FDG) dans l'évaluation de la pathologie pleurale maligne
M. Meignan (2006)
10.1016/J.THORSURG.2004.06.011
Epidemiology, biologic behavior, and natural history of mesothelioma.
L. Zellos (2004)
10.1016/S1569-9293(03)00213-5
Polyhematoporphyrin-mediated photodynamic therapy and decortication in palliation of malignant pleural mesothelioma: a clinical pilot study.
V. Matzi (2004)
10.1002/path.2121
Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma
G. Gordon (2007)
10.4161/cbt.10.5.12616
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma
K. Du (2010)
10.1016/J.HOC.2005.09.008
Antiangiogenic therapies for mesothelioma.
J. Dowell (2005)
10.1200/JCO.2004.22.90140.7199
Identification of glucose transporter type 1 overexpression as a predictor of survival in patients with malignant pleural mesothelioma
D. Fennell (2004)
10.1053/SONC.2002.30227
The pathogenesis of mesothelioma.
M. Carbone (2002)
10.1038/sj.onc.1201493
Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells
C. Craig (1998)
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
V. Macaulay (1999)
10.1007/s11307-009-0203-6
Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
10.1016/S0003-4975(03)00010-9
The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma.
J. H. Schouwink (2003)
10.1016/J.LUNGCAN.2006.08.012
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
J. Edwards (2006)
10.1378/CHEST.128.5.3382
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
F. Demirag (2005)



Semantic Scholar Logo Some data provided by SemanticScholar